Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.61 |
| ▸ | GRM5 | P41594 | 9/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 2/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.43 |
| ▸ | KDM4A | O75164 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16033447 | 0.80 | PHF8 (0.58) | KDM4CKDM5AKDM5BKDM4APHF8 | |
| SCHEMBL16034223 | 0.79 | KDM4C (0.56) | KDM4CGRM5KDM5AKDM5BPHF8 | |
| SCHEMBL16034897 | 0.78 | KDM4C (0.60) | KDM4CGRM5KDM5AKDM5BKDM4A | |
| SCHEMBL16034348 | 0.78 | KDM4C (0.55) | KDM4CKDM5AKDM5BKDM4APHF8 | |
| SCHEMBL16032436 | 0.77 | KDM4C (0.58) | KDM4CGRM5KDM5AKDM5BKDM4A | |
| SCHEMBL16033834 | 0.76 | KDM4C (1.00) | KDM4CKDM5AKDM5BKDM4AKDM4E | |
| SCHEMBL16033745 | 0.76 | KDM5A (0.58) | KDM4CGRM5IRAK4KDM5AKDM5B | |
| SCHEMBL16033817 | 0.76 | PHF8 (0.60) | KDM4CKDM5AKDM5BKDM4APHF8 | |
| SCHEMBL901248 | 0.75 | GRM5 (0.61) | KDM4CGRM5KDM4AKDM4EALDH1A1 | |
| SCHEMBL17706047 | 0.75 | KDM4C (0.47) | KDM4CKDM5AKDM5BKDM4APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2969007-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-2969007-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10273222-B2 | Histone demethylase inhibitors | CELGENE QUANTSCEL RESEARCH, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273222-B2 | Histone demethylase inhibitors | CELGENE QUANTSCEL RESEARCH, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-9963441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-11-23 | — | — | US | disclosed |
| US-20160113914-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| EP-2969007-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9133166-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133166-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133166-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-09-15 | — | — | US | disclosed |
| WO-2014151945-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151945-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273222-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM3B | KDM4C 13/4885GRM5 1728/4885IRAK4 2552/4885 |
| US-20170334879-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 13/4885GRM5 1728/4885IRAK4 2552/4885 |
| US-20140275084-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 13/4885GRM5 1728/4885IRAK4 2552/4885 |
| US-20160113914-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4C 13/4885GRM5 1728/4885IRAK4 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.